The highest evaluated dose of ProLectin-M (16,800 mg/day) achieved statistically significant earlier viral clearance by Day 5 (90%) compared to placebo (20.0%). The highest dose cohort also demonstrated faster clinical improvement by Day 5, with 90% of participants achieving at least a 2-point improvement on the WHO Ordinal Scale, compared to 20.0% in the placebo group. ProLectin-M exhibited a favorable safety and tolerability profile across all evaluated dose levels, with no serious adverse events or treatment-related discontinuations reported. The study enrolled 39 participants in India with RT-PCR-confirmed SARS-CoV-2 infection and mild to moderate disease. While the primary endpoint of viral clearance at Day 7 did not differentiate treatment arms due to the natural resolution of infection in this population, the earlier clearance observed at Day 5 suggests an acceleration of viral resolution.